



PCT/IB 0 4 / 0 0 8 2 2

( 0 9 . 03 . 04 )



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 5 - APR 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*R. Mahoney*

Dated 18 November 2003

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

# Patents Form 1/77

P: Act 1977  
(Rule 16)



17MAR03 E792445-1 D01298  
F01/7700 0.00-0305916.9

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference

PC25367

14 MAR 2003

2. Patent application number

(The Patent Office will fill in this part)

0305916.9

3. Full name, address and postcode of the or of each applicant (underline all surnames)

PFIZER LIMITED  
Ramsgate Road,  
Sandwich,  
Kent, CT13 9NJ

Patents ADP number (if you know it)

United Kingdom

6892673001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

NEW N-PHENPROPYLCYCLOPENTYL-  
SUBSTITUTED GLUTARAMIDE DERIVATIVES AS  
NEP INHIBITORS

5. Name of your agent (if you have one)

Dr. J.E. Rutt

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

UK Patent Department  
Ramsgate Road,  
Sandwich, Kent,  
CT13 9NJ  
United Kingdom

1271001

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

# Patents Form 1/77

- 9 Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	43
Claim(s)	0
Abstract	0
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(*please specify*)

11. I/We request the grant of a patent on the basis of this application.

Signature



13 Date  
March 2003

12. Name and daytime telephone number of person to contact in the United Kingdom
- |               |              |
|---------------|--------------|
| Dr. J.E. Rutt | 01304.648020 |
|---------------|--------------|

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

**New N-Phenpropylcyclopentyl-Substituted Glutaramide Derivatives as NEP****Inhibitors**

The invention relates to inhibitors of neutral endopeptidase enzyme (NEP), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of male and female sexual dysfunction, particularly female sexual dysfunction (FSD), especially wherein the FSD is female sexual arousal disorder (FSAD).

10


NEP inhibitors are disclosed in WO 91/07386 and WO 91/10644.

The use of NEP inhibitors for treating FSD is disclosed in EP1 097 719-A1.

15 The present invention provides a class of potent NEP inhibitors, which have the advantage of being selective for NEP over soluble secreted endopeptidase (SEP). The compounds of the present invention are also selective for NEP over ACE. In addition to their selectivity, the compounds of the present invention also possess unexpectedly good pharmacokinetic properties, in particular good oral bioavailability and suitable  
20 duration of action for *in vivo* efficacy.

According to a first aspect, the invention provides a compound of formula (I), a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof;

25



Wherein:

- 30 R<sup>1</sup> is selected from H or CH<sub>3</sub>  
R<sup>2</sup> is selected from C<sub>1-2</sub> alkyl;  
n is 1-2

And pharmaceutically acceptable salts thereof

The pharmaceutically or veterinarily acceptable salts of the compounds of formula I which contain a basic centre are, for example, non-toxic acid addition salts formed with  
5 inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acid, with carboxylic acids or with organo-sulfonic acids. Examples include the HCl, HBr, HI, sulfate or bisulfate, nitrate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, saccharate, fumarate, maleate, lactate, citrate, tartrate, gluconate, camsylate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate  
10 salts. Compounds of the invention can also provide pharmaceutically or veterinarily acceptable metal salts, in particular non-toxic alkali and alkaline earth metal salts, with bases. Examples include the sodium, potassium, aluminium, calcium, magnesium, zinc, diolamine, olamine, ethylenediamine, tromethamine, chloine, meglumine and diethanolamine salts. For reviews on suitable pharmaceutical salts see Berge *et al*, J.  
15 Pharm, Sci., 66, 1-19, 1977; P L Gould, International Journal of Pharmaceutics, 33 (1986), 201-217; and Bighley *et al*, Encyclopedia of Pharmaceutical Technology, Marcel Dekker Inc, New York 1996, Volume 13, page 453-497.

A pharmaceutically acceptable salt of a compound of the formula (I) may be readily  
20 prepared by mixing together solutions of a compound of the formula (I) and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

Hereinafter, the compounds, their pharmaceutically acceptable salts, their solvates and  
25 polymorphs, defined in any aspect of the invention or preferred embodiment (except intermediate compounds in chemical processes) are referred to as "compounds of the invention".

The pharmaceutically acceptable solvates of the compounds of the invention include  
30 hydrates thereof.

The compounds of the invention and intermediates may possess one or more chiral centres and so exist in a number of stereoisomeric forms. All stereoisomers and mixtures thereof are included in the scope of the present invention.

35

Individual enantiomers may be obtained by a variety of techniques known to the skilled

chemist, such as by high pressure liquid chromatography (HPLC) of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active base, as appropriate.

5

Separation of diastereoisomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C.

10

The compounds of the invention may exist in one or more tautomeric forms. All tautomers and mixtures thereof are included within the scope of the present invention.

15

It will be appreciated by those skilled in the art that certain protected derivatives of compounds of the invention, which may be made prior to a final deprotection stage, may not possess pharmacological activity as such, but may, in certain instances, be administered orally or parenterally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". Further, certain compounds of the invention may act as prodrugs of other compounds of the invention.

20

All protected derivatives and prodrugs of compounds of the invention are included within the scope of the invention. Examples of suitable pro-drugs for the compounds of the present invention are described in Drugs of Today, Volume 19, Number 9, 1983, pp 499 – 538 and in Topics in Chemistry, Chapter 31, pp 306 – 316 and in "Design of Prodrugs" by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures in which documents are incorporated herein by reference).

25

It will further be appreciated by those skilled in the art, that certain moieties, known to those skilled in the art as "pro-moieties", for example as described by H. Bundgaard in "Design of Prodrugs" (the disclosure in which document is incorporated herein by reference) may be placed on appropriate functionalities when such functionalities are present within the compounds of the invention.

30

Preferred prodrugs for compounds of the invention include: esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.

35

The invention also includes all suitable isotopic variations of the compounds of the invention. An isotopic variation is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as  $^2\text{H}$ ,  $^3\text{H}$ ,  $^{13}\text{C}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{17}\text{O}$ ,  $^{18}\text{O}$ ,  $^{31}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{18}\text{F}$  and  $^{36}\text{Cl}$ , respectively. Certain isotopic variations of the invention, for example, those in which a radioactive isotope such as  $^3\text{H}$  or  $^{14}\text{C}$  is incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e.  $^3\text{H}$ , and carbon-14, i.e.  $^{14}\text{C}$  isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e.  $^2\text{H}$ , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the compounds of the invention can generally be prepared by conventional procedures such as by the methods or preparations described in the Examples and Preparations hereafter using appropriate isotopic variations of suitable reagents.


A preferred aspect of the invention are compounds of formula (I) are those where n is 1.  
In another preferred embodiment  $\text{R}^1$  is methyl.  
In yet another preferred embodiment  $\text{R}^2$  is methyl

In a particularly preferred embodiment of the present invention are compounds of formula (I) wherein  $\text{R}^1$  is methyl,  $\text{R}^2$  is methyl and n is 1;  $\text{R}^1$  is hydrogen  $\text{R}^2$  is ethyl and n is 1; and  $\text{R}^1$  is methyl,  $\text{R}^2$  is ethyl and n is 1

Compounds of the invention may be prepared in known manner in a variety of ways. In the following reaction schemes and hereafter, unless otherwise stated,  $\text{R}^1$ ,  $\text{R}^2$  and n are as defined in the first aspect. These processes form further aspects of the invention.

Throughout the specification, general formulae are designated by Roman numerals I, II, III, IV etc. Subsets of these general formulae are defined as Ia, Ib, Ic etc, .... IVa, IVb, IVc etc.

Compounds of formula (I) may be prepared by the following process as described in scheme (I) below:



5

Compounds of formula (IV) may be prepared by reacting compounds of formula (II) and (III) under the conditions of process step (a) Amide bond formation – such reactions may be carried out under a wide variety of conditions well known to the skilled man.

- 10 Typically - The carboxylic acid may be activated by treatment with an agent such as 1,1'-carbonyldiimidazole (CDI), fluoro-*N,N,N',N'*-tetramethylformamidinium hexafluorophosphate (TFFH), or a combination of reagents such as azabenzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP) and 1-hydroxy-7-azabenzotriazole (HOAt). Alternatively, the reaction may be carried out by addition of a
- 15 peptide coupling agent such as *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-uranium hexafluorophosphate (HATU), or *O*-benzotriazol-1-yl-*N,N,N',N'*-uranium hexafluorophosphate (HBTU), or *N,N'*-dicyclohexylcarbodiimide (DCC), 1,3-

diisopropylcarbodiimide (DIC) to a mixture of the acid and amine. The reaction is carried out in a suitable solvent such as CH<sub>2</sub>Cl<sub>2</sub>, Pyridine, *N,N*-dimethylformamide (DMF), *N,N*-dimethylacetamide (DMA) or 1-methyl-2-pyrrolidinone between 0 °C and the boiling point of the solvent.

5

Preferably the conversion is effected using CDI, triethylamine and isopropyl acetate as solvent.

10

The product of process step (a) is then treated under the conditions of process step (b)  
Removal of protecting group PG. Suitable groups are described in "Protective Groups in Organic Synthesis" by T. W. Greene and P. G. M. Wuts, John Wiley and Sons Inc, 1991.

15

The conditions required for removal of the protecting group are often specific to that protecting group; conditions for their removal may be found in references such as  
Greene T.W., Wuts, P.G.M. Protective Groups in Organic Synthesis, Wiley-Interscience and Kocienski, P.J. Protecting Groups, Thieme.


20

Preferably PG is a *tert*-butyl group and deprotection is acid catalysed using a suitable solvent at room temperature. Preferred conditions are trifluoroacetic acid in dichloromethane.

Compounds of formula (II) and (III) may be prepared according to the processes described in WO02/079143.

25

In addition, compounds of formula (III) may be prepared as described below:



- Compounds of formula (VII) may be prepared from compounds of formula (V) and (VI) under the conditions of process step (c) an aryl-allyl coupling. Suitable conditions are well known to a man skilled in the art. Particularly suitable conditions are those of the Suzuki-Miyaura coupling reaction [*Angew. Chem. Int. Ed.* **2001**, *40*(24), 4544-4568] with a hydroborated intermediate, prepared from an appropriately protected allylamine derivative (e.g. Di(*tert*-butyl) allylimidodicarbonate *Bioorganic & Medicinal Chemistry Letters*, **1999**, *7*, 1625-1636) and a borane derivative, such as 9-BBN.
- Compounds of formula (III) may be prepared from compounds of formula (VII) under the conditions of process step (b) Removal of protecting group PG described herein.

All of the above reactions and the preparations of novel starting materials used in the preceding methods are conventional. Appropriate reagents and reaction conditions for their performance or preparation as well as procedures for isolating the desired products will be well-known to those skilled in the art with reference to literature precedents and the Examples and Preparations hereinbelow.



The compounds of the present invention are a class of NEP inhibitors, selective for NEP over SEP.

5 In general it is important for a drug to be as selective as possible for its desired target enzyme; additional activities give rise to the possibility of side effects. SEP was relatively recently identified and its exact physiological role has yet to be fully determined. However, irrespective of whatever role SEP may or may not play, it is a sound medicinal chemistry precept to ensure that any drug has selectivity over closely related mechanistic targets of unknown physiological function.

10

Without being bound by any theory it is becoming clear that NEP and SEP are capable of hydrolysing many of the same biologically important peptides such as enkaphalin, endothelin (ET), big-endothelin (Big ET), bradykinin, substance P, angiotensin1, atrial natriuretic peptide (ANP), and gonadotropic releasing hormone (GnRH).

15

If a patient is treated with a drug that inhibits NEP and SEP, the hydrolysis of many of these peptides (most of which are not involved with the improvement in sexual function associated with NEP inhibition) may be reduced and the levels of these peptides will therefore increased. A number of side effects associated with a rise in the levels of these peptides may be posited: blood pressure may be lowered when ANP levels are increased; increases in enkephalin levels may lead to changes in pain perception; endothelin-1 is a potent vasoconstrictor, reducing the levels of conversion of Big ET to ET, or the hydrolysis of ET-1 may lead to changes in blood pressure; GnRH plays an important role in growth and maintainance of the placenta, thus increases in levels of GnRH could effect the placenta

20

25

Thus if the patient is given a NEP selective inhibitor, the increases in levels of these substrate peptides will be less since active SEP enzyme will still be present. Any side effects associated with changes in levels of these peptides will therefore also be less.

30

In addition the mRNA for SEP is particularly abundant in the testes (Bonvouloir et al DNA and cell biol. (20) 8 p493-498). SEP mRNA can also be found in other tissues at low levels, including in the heart, brain, kidney, salivary glands, thyroid glands, placenta, small intestine and ovary (in house data and Bonvouloir et al). In the case of mice, SEP RNA has also been detected in the spleen and adrenal glands. A NEP inhibitor that does

35

not inhibit SEP is therefore likely to have the advantage of a greater potential for a cleaner physiological profile.

5 Surprisingly, in identifying a class of NEP inhibitors selective over SEP, it has been discovered that these compounds have favourable pharmacokinetic properties for oral administration.

10 An orally administered drug should have good bioavailability – that is an ability to readily cross the gastrointestinal (GI) tract and have a metabolic rate such that it is not subject to extensive metabolism as it passes from the GI tract into the systemic circulation. Molecules which are quickly metabolised will have lower bioavailability as more compound will be removed by metabolism as it passes into the systemic circulation. Once a drug is in the systemic circulation the metabolic rate is also important in determining the time of residence of the drug in the body - fast metabolism of a drug will  
15 lead to it having a short duration of action:

Thus, it is clearly favourable for drug molecules have the properties of being readily able to cross the GI tract, and being only slowly metabolised in the body.

20 The CACO-2 assay is a widely accepted model for predicting the ability of a given molecule to cross the GI tract. The molecules of the present invention have good CACO-2 flux.

25 The majority of metabolism of drug molecules generally occurs in the liver. Therefore the use of human liver microsomes (HLM) is a widely accepted method for measuring the susceptibility of a given molecule towards metabolism in the liver. The compounds of the present invention are stable towards HLM.

30 Compounds which have good CACO-2 flux, and are stable towards HLM are predicted to have good oral bioavailability (good absorption across the GI tract and minimal extraction of compound as it passes through the liver) and a long residence time in the body - sufficient for the drug to be efficacious.

35 Additionally the compounds of the invention are crystalline in the free acid form, without recourse to salt formation and are thus particularly easy to handle.



The compounds of the invention are inhibitors of the zinc-dependent, neutral endopeptidase EC.3.4.24.11., and it is proposed that the compounds of the invention will treat the disease states listed below. This enzyme is involved in the breakdown of several bioactive oligopeptides, cleaving peptide bonds on the amino side of hydrophobic amino acid residues. The peptides metabolised include atrial natriuretic peptides (ANP), bombesin, bradykinin, calcitonin gene-related peptide, endothelins, enkephalins, neurotensin, substance P and vasoactive intestinal peptide. Some of these peptides have potent vasodilatory and neurohormone functions, diuretic and natriuretic activity or mediate behaviour effects.

10

Thus, the compounds of the invention, by inhibiting the neutral endopeptidase EC.3.4.24.11, can potentiate the biological effects of bioactive peptides. Thus, in particular the compounds have utility in the treatment of a number of disorders, including hypertension, pulmonary hypertension, peripheral vascular disease, heart failure, angina, renal insufficiency, acute renal failure, cyclical oedema, Menière's disease, hyperaldosteronism (primary and secondary) and hypercalciuria. The term hypertension includes all diseases characterised by supranormal blood pressure, such as essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, and renovascular hypertension, and further extends to conditions for which elevated blood pressure is a known risk factor. Accordingly, the term "treatment of hypertension" includes the treatment or prevention of complications arising from hypertension, and other associated co-morbidities, including congestive heart failure, angina, stroke, glaucoma, impaired renal function, including renal failure, obesity, and metabolic diseases (including Metabolic Syndrome). Metabolic diseases include in particular diabetes and impaired glucose tolerance, including complications thereof, such as diabetic retinopathy and diabetic neuropathy.

25

In addition, because of their ability to potentiate the effects of ANF the compounds have utility in the treatment of glaucoma. As a further result of their ability to inhibit the neutral endopeptidase E.C.3.4.24.11 the compounds of the invention may have activity in other therapeutic areas including for example the treatment of menstrual disorders, preterm labour, pre-eclampsia, endometriosis, and reproductive disorders (especially male and female infertility, polycystic ovarian syndrome, implantation failure). Also the compounds of the invention should treat asthma, inflammation, leukemia, pain, epilepsy, affective

35

disorders, dementia and geriatric confusion, obesity and gastrointestinal disorders (especially diarrhoea and irritable bowel syndrome), wound healing (especially diabetic and venous ulcers and pressure sores), septic shock, the modulation of gastric acid secretion, the treatment of hyperreninaemia, cystic fibrosis, restenosis, diabetic  
5 complications and atherosclerosis.

In a preferred embodiment the compounds of the invention are useful in the treatment of male and female sexual dysfunction. The compounds of the invention are particularly beneficial for the treatment of FSD (especially FSAD) and male sexual dysfunction  
10 (especially male erectile dysfunction (MED)).

In accordance with the invention, FSD can be defined as the difficulty or inability of a woman to find satisfaction in sexual expression. FSD is a collective term for several diverse female sexual disorders (Leiblum, S.R. (1998). Definition and classification of  
15 female sexual disorders. *Int. J. Impotence Res.*, 10, S104-S106; , Berman, J.R., Berman, L. & Goldstein, I. (1999). Female sexual dysfunction: Incidence, pathophysiology, evaluations and treatment options. *Urology*, 54, 385-391). The woman may have lack of desire, difficulty with arousal or orgasm, pain with intercourse or a combination of these problems. Several types of disease, medications, injuries or  
20 psychological problems can cause FSD. Treatments in development are targeted to treat specific subtypes of FSD, predominantly desire and arousal disorders.

The categories of FSD are best defined by contrasting them to the phases of normal female sexual response: desire, arousal and orgasm (Leiblum, S.R. (1998). Definition  
25 and classification of female sexual disorders. *Int. J. Impotence Res.*, 10, S104-S106). Desire or libido is the drive for sexual expression. Its manifestations often include sexual thoughts either when in the company of an interested partner or when exposed to other erotic stimuli. Arousal is the vascular response to sexual stimulation, an important component of which is genital engorgement and includes increased vaginal lubrication,  
30 elongation of the vagina and increased genital sensation/sensitivity. Orgasm is the release of sexual tension that has culminated during arousal.

Hence, FSD occurs when a woman has an inadequate or unsatisfactory response in any of these phases, usually desire, arousal or orgasm. FSD categories include hypoactive  
35 sexual desire disorder, sexual arousal disorder, orgasmic disorders and sexual pain disorders. Although the compounds of the invention will improve the genital response to

sexual stimulation (as in female sexual arousal disorder), in doing so it may also improve the associated pain, distress and discomfort associated with intercourse and so treat other female sexual disorders.

- 5 Hypoactive sexual desire disorder is present if a woman has no or little desire to be sexual, and has no or few sexual thoughts or fantasies. This type of FSD can be caused by low testosterone levels, due either to natural menopause or to surgical menopause. Other causes include illness, medications, fatigue, depression and anxiety.
- 10 Female sexual arousal disorder (FSAD) is characterised by inadequate genital response to sexual stimulation. The genitalia do not undergo the engorgement that characterises normal sexual arousal. The vaginal walls are poorly lubricated, so that intercourse is painful. Orgasms may be impeded. Arousal disorder can be caused by reduced oestrogen at menopause or after childbirth and during lactation, as well as by illnesses,  
15 with vascular components such as diabetes and atherosclerosis. Other causes result from treatment with diuretics, antihistamines, antidepressants (e.g. SSRIs) or antihypertensive agents.
- 20 Sexual pain disorders (e.g. dyspareunia and vaginismus) is characterised by pain resulting from penetration and may be caused by medications which reduce lubrication, endometriosis, pelvic inflammatory disease, inflammatory bowel disease or urinary tract problems.
- 25 The prevalence of FSD is difficult to gauge because the term covers several types of problem, some of which are difficult to measure, and because the interest in treating FSD is relatively recent. Many women's sexual problems are associated either directly with the female ageing process or with chronic illnesses such as diabetes and hypertension.
- 30 Because FSD consists of several subtypes that express symptoms in separate phases of the sexual response cycle, there is not a single therapy. Current treatment of FSD focuses principally on psychological or relationship issues. Treatment of FSD is gradually evolving as more clinical and basic science studies are dedicated to the investigation of this medical problem. Female sexual complaints are not all  
35 psychological in pathophysiology, especially for those individuals who may have a component of vasculogenic dysfunction (eg FSAD) contributing to the overall female

sexual complaint. There are at present no drugs licensed for the treatment of FSD. Empirical drug therapy includes oestrogen administration (topically or as hormone replacement therapy), androgens or mood-altering drugs such as buspirone or trazodone. These treatment options are often unsatisfactory due to low efficacy or unacceptable side effects.

Since interest is relatively recent in treating FSD pharmacologically, therapy consists of the following:- psychological counselling, over-the-counter sexual lubricants, and investigational candidates, including drugs approved for other conditions. These medications consist of hormonal agents, either testosterone or combinations of oestrogen and testosterone and more recently vascular drugs, that have proved effective in male erectile dysfunction. None of these agents has been demonstrated to be very effective in treating FSD.

The Diagnostic and Statistical Manual (DSM) IV of the American Psychiatric Association defines Female Sexual Arousal Disorder (FSAD) as being: "a persistent or recurrent inability to attain or to maintain until completion of the sexual activity adequate lubrication-swelling response of sexual excitement. The disturbance must cause marked distress or interpersonal difficulty."

The arousal response consists of vasocongestion in the pelvis, vaginal lubrication and expansion and swelling of the external genitalia. The disturbance causes marked distress and/or interpersonal difficulty.

FSAD is a highly prevalent sexual disorder affecting pre-, peri- and post menopausal ( $\pm$  HRT) women. It is associated with concomitant disorders such as depression, cardiovascular diseases, diabetes and UG disorders.

The primary consequences of FSAD are lack of engorgement/swelling, lack of lubrication and lack of pleasurable genital sensation. The secondary consequences of FSAD are reduced sexual desire, pain during intercourse and difficulty in achieving an orgasm.

It has recently been hypothesised that there is a vascular basis for at least a proportion of patients with symptoms of FSAD (Goldstein *et al.*, Int. J. Impot. Res., 10, S84-

S90,1998) with animal data supporting this view (Park *et al.*, Int. J. Impot. Res., 9, 27-37, 1997).

5 Drug candidates for treating FSAD, which are under investigation for efficacy, are primarily erectile dysfunction therapies that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors e.g. Sildenafil), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethrally in men, and topically to the genitalia in women.

10

The compounds of the invention are advantageous by providing a means for restoring a normal sexual arousal response - namely increased genital blood flow leading to vaginal, clitoral and labial engorgement. This will result in increased vaginal lubrication *via* plasma transudation, increased vaginal compliance and increased genital sensitivity.  
15 Hence, the compounds of the invention provide means to restore, or potentiate, the normal sexual arousal response.

Without being bound by theory, we believe that neuropeptides such as vasoactive intestinal peptide (VIP) are major neurotransmitter candidates in the control of the  
20 female sexual arousal response, especially in the control of genital blood flow. VIP and other neuropeptides are degraded/ metabolised by NEP EC3.4.24.11. Thus, NEP inhibitors will potentiate the endogenous vasorelaxant effect of VIP released during arousal. This will lead to a treatment of FSAD, such as through enhanced genital blood flow and hence genital engorgement. We have shown that selective inhibitors of NEP  
25 EC 3.4.24.11 enhance pelvic nerve-stimulated and VIP-induced increases in vaginal and clitoral blood flow. In addition, selective NEP inhibitors enhance VIP and nerve-mediated relaxations of isolated vagina wall.

Thus the present invention is advantageous as it helps provide a means for restoring a  
30 normal sexual arousal response - namely increased genital blood flow leading to vaginal, clitoral and labial engorgement. This will result in increased vaginal lubrication *via* plasma transudation, increased vaginal compliance and increased vaginal sensitivity. Hence, the present invention provides a means to restore, or potentiate the normal sexual arousal response.

35

Male sexual dysfunction includes male erectile dysfunction, ejaculatory disorders such as premature ejaculation (PE), anorgasmia (inability to achieve orgasm) and desire disorders such as hypoactive sexual desire disorder (lack of interest in sex).

- 5 It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.

The compounds of the invention find application in the following sub-populations of patients with FSD: the young, the elderly, pre-menopausal, peri-menopausal, post-  
10 menopausal women with or without hormone replacement therapy.

The compounds of the invention find application in patients with FSD arising from:-

- i) Vasculogenic etiologies eg cardiovascular or atherosclerotic diseases, hypercholesterolemia, cigarette smoking, diabetes, hypertension, radiation and  
15 perineal trauma, traumatic injury to the iliohypogastric pudendal vascular system.
- ii) Neurogenic etiologies such as spinal cord injuries or diseases of the central nervous system including multiple sclerosis, diabetes, Parkinsonism, cerebrovascular accidents, peripheral neuropathies, trauma or radical pelvic surgery.
- 20 iii) Hormonal/endocrine etiologies such as dysfunction of the hypothalamic/pituitary/gonadal axis, or dysfunction of the ovaries, dysfunction of the pancreas, surgical or medical castration, androgen deficiency, high circulating levels of prolactin eg hyperprolactinemia, natural menopause, premature ovarian failure, hyper and hypothyroidism.
- 25 iv) Psychogenic etiologies such as depression, obsessive compulsive disorder, anxiety disorder, postnatal depression/"Baby Blues", emotional and relational issues, performance anxiety, marital discord, dysfunctional attitudes, sexual phobias, religious inhibition or a traumatic past experiences.
- v) Drug-induced sexual dysfunction resulting from therapy with selective serotonin  
30 reuptake inhibitors (SSRIs) and other antidepressant therapies (tricyclics and major tranquillizers), anti-hypertensive therapies, sympatholytic drugs, chronic oral contraceptive pill therapy.

Patients with mild to moderate MED should benefit from treatment with a compound of  
35 the invention and patients with severe MED may also respond. However, early investigations suggest that the responder rate of patients with mild, moderate and

severe MED will be greater in combination with a PDE5 inhibitor. Mild, moderate and severe MED will be terms known to the man skilled in the art, but guidance can be found in *The Journal of Urology*, vol 151, 54-61 (Jan 1994).

- 5 The compounds of the invention find application in the following sub-populations of patients with MED: psychogenic, endocrinologic, neurogenic, arteriogenic, drug-induced sexual dysfunction (lactogenic) and sexual dysfunction related to cavernosal factors, particularly venogenic causes. These patient groups are described in more detail in Clinical Andrology vol 23,no.4, p773-782, and chapter 3 of the book by I. Eardley and K. Sethia "Erectile Dysfunction - Current Investigation and Management, published by Mosby-Wolfe.

### **Assay conditions**

#### **15 Production of native NEP enzyme:**

NEP is isolated from kidneys following the method described by Kenny and Booth (Booth, A.G. & Kenny, A.J. (1974) *Biochem. J.* 142, 575-581).

#### **20 Production of recombinant SEP enzyme.**

Recombinant SEP enzyme is produced in house using one of two alternative methods

- 25 **Method1:** A culture of Chinese Hamster Ovary (CHO) cells is transfected with the plasmid NCIMB deposit number 41110 using the lipofectamine method as described in the lipofectamine reagent protocol (Invitrogen Ltd, Paisley, UK). The cell media is harvested at 24 or 48 hours post transfection, and cleared of cell debris by centrifugation at 3000g for 5 min. The media is then dialyzed overnight at 4° C  
30 against 50mM HEPES pH7.4/10% glycerol, using a "slide a lyser" from Pierce and Warner, Chester UK. The dialyzed sample is then frozen in aliquots and stored under liquid nitrogen.

- 35 **Method2:** A stable human embryonic kidney (HEK) cell line producing recombinant SEP has been made in house according to standard molecular and cell biology methods. This HEK-SEP cell line is cultured in flasks or roller bottles according to standard protocols for HEK cells, in media supplemented with hygromycin B. Media is collected and centrifuged at 3000g for 15 minutes at room temperature to remove the cell debris, then dialysed with dialysis buffer (50mM HEPES pH7.4/10% glycerol)  
40 for at least 6 hours, using a "slide a lyser" from Pierce and Warner, Chester UK, with at least one change of dialysis buffer during the 6 hours.

### **Assay of SEP or NEP peptidase activity**

The peptidase activity of SEP or NEP is measured by monitoring its ability to proteolyse the synthetic peptide substrate Rhodamine green-Gly-Gly- $\alpha$ Phe-Leu-Arg-Arg-Val-Cys(QSY7)- $\beta$ Ala-NH<sub>2</sub> :

5 Reagents for the assay are first prepared as follows:

A substrate solution is made up by diluting a 2mM/100%DMSO Rhodamine green-Gly-Gly- $\alpha$ Phe-Leu-Arg-Arg-Val-Cys(QSY7)- $\beta$ Ala-NH<sub>2</sub> stock solution in 50mM HEPES buffer pH7.4 (Sigma, UK) at a concentration of 2 $\mu$ M.

10

An aliquot of SEP or NEP enzyme described above is thawed then diluted in 50mM HEPES, pH7.4 containing 1 EDTA free protease inhibitor cocktail tablet (Roche Diagnostics, UK) per 25ml. The dilution is by a predetermined factor specific to each enzyme batch, such that 15 $\mu$ l contains sufficient enzyme to convert approximately 30% of substrate to product during the assay.

15

A 4% DMSO solution comprised of 4mls DMSO plus 96ml 50mM HEPES pH7.4 is prepared.

20

A product solution is prepared by adding 500 $\mu$ l of substrate solution to 250  $\mu$ l enzyme solution plus 250 $\mu$ l of 4% DMSO solution, and incubating at 37°C for 16 hours.

Assays are set up as follows:

25

In a black 384 well microtitre plate, 15 $\mu$ l of enzyme solution is added to 15 $\mu$ l of 4% DMSO solution. A similar non-specific background blank is also set up in which the 15 $\mu$ l of 4% DMSO solution additionally contains 40 $\mu$ M phosphoramidon. 30 $\mu$ l of substrate solution is then added to both the assay and blank, then the plate is incubated for 1 hour at 37°C. Following incubation a fluorescence measurement is taken (Ex485 / Em538). BMG galaxy fluorescence reader (BMG Lab technologies, Offenber, Germany).

30

The proteolytic activity of the enzyme corresponds to the fluorescence of the sample minus the fluorescence of the non-specific background blank.

35

A fluorescence measurement taken from 60 $\mu$ l of product in a well on an identical microtitre plate may be taken. If required this value is used, together with the measured fluorescence units from the SEP assay to calculate the % of the substrate proteolysed during the 1 hour incubation period or to convert the measured fluorescence increase into other useful units such as ng substrate proteolysed/min/ml enzyme.

40

Using the assay to determine the IC<sub>50</sub>'s of NEP and SEP inhibitors.

45

To determine the IC<sub>50</sub> of SEP or NEP inhibitors (for example phosphoramidon), multiple assays are performed as described above with a range of test concentrations of inhibitor included in the 15 $\mu$ l of DMSO solution. (Made by appropriate dilution of a 10mM 100% DMSO stock of inhibitor with 4 % DMSO/50mM HEPES pH7.4.) Using a suitable standard graph fitting computer

program, a sigmoidal dose response curve is fitted to a plot of log inhibitor concentration vs % inhibition or % activity. The  $IC_{50}$  is calculated as the inhibitor concentration causing 50 % maximal inhibition. Typically for a given  $IC_{50}$  determination, a dose range of at least 10 inhibitor concentrations used differing in half log unit increments is used.

For inhibitors that give an  $IC_{50}$  result less than approximately 2nM, the assay is repeated under modified assay conditions in which: The quantity of enzyme used is reduced to approx  $1/10^{th}$  to  $1/20^{th}$ ; The substrate concentration is increased to 5uM; and the incubation time increased to 3 hours. This lowers the potency limit (tight binding limit) of the assay to a level where The  $IC_{50}$  estimate of compounds whose  $K_i$  is in the range of  $\sim 0.2$ -2nM are not limited by the enzyme concentration.

The compounds of the present invention have been tested in the assays above. All the compounds are potent NEP inhibitors with an  $IC_{50}$  of  $<2$  nanomolar and a selectivity for NEP over SEP of at least 1000 fold.

(*R*)-2-Methyl-3-(1-[[3-(2-methyl-1,3-benzothiazol-6-yl)propyl]carbamoyl]cyclopentyl)propanoic acid (Example 1) has an activity against NEP expressed as an  $IC_{50}$  of 1nm and 1900 fold selectivity for NEP over SEP.

The utility of the compounds of the present invention to treat FSD and MED may be further determined using the techniques described in WO02/079143.

25

The advantageous pharmacokinetics of the compounds of the present invention may be demonstrated by using the CaCO-2 test. The CACO-2 assay is a widely accepted model for predicting the ability of a given molecule to cross the GI tract. The compounds of the present invention have good CACO-2 flux defined as follows. Compounds with an apparent permeability ( $P_{app}$ ) value in CACO-2 cells of  $>5 \times 10^{-6}$  cm/s (at pH 7.4) and  $>15 \times 10^{-6}$  cm/s (at pH 6.5) are considered to have good permeability and predicted to be well absorbed across the GI tract.

30

The test is conducted as described below:

35

#### Cell culture

Caco-2 cells were seeded in 24-well Falcon Multiwell® plates at  $4.0 \times 10^4$  cells/well. The cells were grown in culture media consisting of minimum essential medium (Gibco 21090-022) supplemented 20% Fetal Bovine serum, 1% non-essential amino acids, 2mM L-glutamine and 2mM sodium pyruvate. The culture medium was replaced three times every week and the cells were maintained at 37 °C, with

40

5% CO<sub>2</sub> and at 90% relative humidity. Permeability studies were conducted when the monolayers were between 15 and 18 days old. Cells were used between passage 23 and 40.

## 5 Permeability Studies

Each test compound was prepared as a 10mM DMSO solution, 62.5 µl of this solution was then added to 25mL of transport buffer. Nadolol (25µM) was added to every well as a marker of membrane integrity. These solutions along with transport buffer were then warmed to 37 °C. Transport buffer was HBSS (Hank's balanced salt solution) at pH 7.4 or pH 6.5. Before the commencing each study each monolayer was washed three times with HBSS. Transport Buffer with no compound added was placed in each acceptor well, 250 µl on the apical side and 1mL into the basolateral well. The study was commenced by adding drug solution to each donor well, 250 µl to the apical wells and 1mL to the basolateral well. Following a two-hour incubation at 37 °C for two hours samples were removed from all wells for LC-MS-MS analysis.

The compounds of the present invention have a CACO-2 A-B flux > 5.

Human liver microsomes are a widely accepted model for predicting the metabolic stability of drug molecules towards metabolism in the liver. The compounds of the present invention are stable towards metabolism by HLM. Compounds with a half-life in HLM of <90mins are metabolised too quickly and are predicted to show a prohibitively short residence time in the body, and reduced bioavailability compared to metabolically stable compounds. The compounds of the present invention have half lives in HLM of >110mins.

The test is conducted as follows:

**30 Microsomal incubations.** All incubations were carried out in a thermostatted shaking water-bath at 37 °C. Each incubate contained 0.5µM CYP. Cofactors were added as NADPH regenerating system. It consisted of 1.2 mM NADP, 5 mM MgCl<sub>2</sub> x 6H<sub>2</sub>O, 5mM DL-isocitric acid and 1unit/ml isocitric dehydrogenase, highly purified. All reagents were dissolved in phosphate buffer (50 mM; pH 7.4). The substrate concentration was 1µM.

**35** Substrates were dissolved in acetonitril with the final acetonitril concentration in the incubation mixture lower than 0.1% (v/v). NADP was omitted from control incubations. In all experiments, samples were pre-incubated with microsomes, substrate and

regenerating system in the absence of NADP for 5 min at 37 °C. The reaction was started by addition of NADP. Incubation time was 1h. 100µl aliquots were removed after 0, 3, 5, 10, 15, 20, 30, 45 & 60 min. The aliquots were extracted with 400µl 1M-acetic acid and 2.0ml of ethylacetate and analysed by LC-MS-MS.

5

The compounds of the may be combined with one or more further active ingredients selected from the list:

- 1) One or more naturally occurring or synthetic prostaglandins or esters thereof.  
 10 Suitable prostaglandins for use herein include compounds such as alprostadiol, prostaglandin E<sub>1</sub>, prostaglandin E<sub>0</sub>, 13, 14 - dihydroprosta glandin E<sub>1</sub>, prostaglandin E<sub>2</sub>, eprostinol, natural synthetic and semi-synthetic prostaglandins and derivatives thereof including those described in WO-00033825 and/or US 6,037,346 issued on 14th March 2000 all incorporated herein by reference,  
 15 PGE<sub>0</sub>, PGE<sub>1</sub>, PGA<sub>1</sub>, PGB<sub>1</sub>, PGF<sub>1</sub> α, 19-hydroxy PGA<sub>1</sub>, 19-hydroxy - PGB<sub>1</sub>, PGE<sub>2</sub>, PGB<sub>2</sub>, 19-hydroxy-PGA<sub>2</sub>, 19-hydroxy-PGB<sub>2</sub>, PGE<sub>3</sub>α, carboprost tromethamine dinoprost, tromethamine, dinoprostone, lipo prost, gemeprost, metenoprost, sulprostune, tiaprost and moxisylate.
- 2) One or more α - adrenergic receptor antagonist compounds also known as α -  
 20 adrenoceptors or α-receptors or α-blockers. Suitable compounds for use herein include: the α-adrenergic receptor blockers as described in PCT application WO99/30697 published on 14th June 1998, the disclosures of which relating to α-adrenergic receptors are incorporated herein by reference and include, selective α<sub>1</sub>-adrenoceptor or α<sub>2</sub>-adrenoceptor blockers and non-selective  
 25 adrenoceptor blockers, suitable α<sub>1</sub>-adrenoceptor blockers include: phentolamine, phentolamine mesylate, trazodone, alfuzosin, indoramin, naftopidil, tamsulosin, dapiprazole, phenoxybenzamine, idazoxan, efaraxan, yohimbine, rauwolfia alkaloids, Recordati 15/2739, SNAP 1069, SNAP 5089, RS17053, SL 89.0591, doxazosin, terazosin, abanoquil and prazosin; α<sub>2</sub>-blocker blockers from US  
 30 6,037,346 [14th March 2000] dibenarnine, tolazoline, trimazosin and dibenarnine; α-adrenergic receptors as described in US patents: 4,188,390; 4,026,894; 3,511,836; 4,315,007; 3,527,761; 3,997,666; 2,503,059; 4,703,063; 3,381,009; 4,252,721 and 2,599,000 each of which is incorporated herein by reference; α<sub>2</sub>- Adrenoceptor blockers include: clonidine, papaverine, papaverine hydrochloride,  
 35 optionally in the presence of a cariotonic agent such as pirxamine.

- 3) One or more NO-donor (NO-agonist) compounds. Suitable NO-donor compounds for use herein include organic nitrates, such as mono- di or tri-nitrates or organic nitrate esters including glyceryl brinitrate (also known as nitroglycerin), isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside (SNP), 3-morpholinomethyl nitroimidazole-5-carboxylate (molsidomine), S-nitroso- N-acetyl penicillamine (SNAP) S-nitroso-N-glutathione (SNO-GLU), N-hydroxy - L-arginine, amyl nitrate, linsidomine, linsidomine hydrochloride, (SIN-1) S-nitroso - N-cysteine, diazenium diolates, (NONOates), 1,5-pentanedinitrate, L-arginine, ginseng, zizphi fructus, molsidomine, Re – 2047, nitrosylated maxisylate derivatives such as NMI-678-11 and NMI-937 as described in published PCT application WO 0012075.
- 4) One or more potassium channel openers or modulators. Suitable potassium channel openers/modulators for use herein include nicorandil, cromakalim, levcromakalim, lemakalim, pinacidil, cliazoxide, minoxidil, charybdotoxin, glyburide, 4-aminopyridine, BaCl<sub>2</sub>.
- 5) One or more dopaminergic agents, preferably apomorphine or a selective D<sub>2</sub>, D<sub>3</sub> or D<sub>2</sub>/D<sub>3</sub>agonist such as, pramipexole and ropirinol (as claimed in WO-0023056), PNU95666 (as claimed in WO-0040226).
- 6) One or more vasodilator agents. Suitable vasodilator agents for use herein include nimodipine, pinacidil, cyclandelate, isoxsuprine, chlorpromazine, haloperidol, Rec 15/2739, trazodone.
- 7) One or more thromboxane A<sub>2</sub> agonists.
- 8) One or more CNS active agents.
- 9) One or more ergot alkaloids. Suitable ergot alkaloids are described in US patent 6,037,346 issued on 14th March 2000 and include acetergamine, brazergoline, bromerguride, cianergoline, delorgotril, disulergine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotril, lysergide, mesulergine, metergoline, metergotamine, nicergoline, pergolide, propisergide, proterguride, terguride.
- 10) One or more compounds which modulate the action of natriuretic factors in particular atrial natriuretic factor (also known as atrial natriuretic peptide), B type and C type natriuretic factors such as inhibitors or neutral endopeptidase.
- 11) One or more compounds which inhibit angiotensin-converting enzyme such as enalapril, and combined inhibitors of angiotensin-converting enzyme and neutral endopeptidase such as omapatrilat.
- 12) One or more angiotensin receptor antagonists such as losartan.
- 13) One or more substrates for NO-synthase, such as L-arginine.



- 14) One or more calcium channel blockers such as amlodipine.
- 15) One or more antagonists of endothelin receptors and inhibitors or endothelin-converting enzyme.
- 16) One or more cholesterol lowering agents such as statins (e.g. atorvastatin/  
5 Lipitor- trade mark) and fibrates.
- 17) One or more antiplatelet and antithrombotic agents, e.g. tPA, uPA, warfarin, hirudin and other thrombin inhibitors, heparin, thromboplastin activating factor inhibitors.
- 18) One or more insulin sensitising agents such as rezulin and hypoglycaemic agents  
10 such as glipizide.
- 19) L-DOPA or carbidopa.
- 20) One or more acetylcholinesterase inhibitors such as donezipil.
- 21) One or more steroidal or non-steroidal anti-inflammatory agents.
- 22) One or more estrogen receptor modulators and/or estrogen agonists and/or  
15 estrogen antagonists, preferably raloxifene, tibolone or lasofoxifene, (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol and pharmaceutically acceptable salts thereof the preparation of which is detailed in WO 96/21656.
- 23) One or more modulators of cannabinoid receptors.
- 20 24) One or more of an NPY (neuropeptide Y) inhibitor, more particularly NPY1 or NPY5 inhibitor, preferably NPY1 inhibitor, preferably said NPY inhibitors (including NPY Y1 and NPY Y5) having an IC<sub>50</sub> of less than 100nM , more preferably less than 50nM. An assay for identifying NPY inhibitors is presented in WO-A-98/52890 (see page 96, lines 2 to 28).
- 25 25) One or more of vasoactive intestinal protein (VIP), VIP mimetic, VIP analogue, more particularly mediated by one or more of the VIP receptor subtypes VPAC1,VPAC or PACAP (pituitary adenylate cyclase activating peptide), one or more of a VIP receptor agonist or a VIP analogue (eg Ro-125-1553) or a VIP fragment, one or more of a  $\alpha$ -adrenoceptor antagonist with VIP combination (eg  
30 Invicorp, Aviptadil).
- 26) One or more of a melanocortin receptor agonist or modulator or melanocortin enhancer, such as melanotan II, PT-14, PT-141 or compounds claimed in WO-09964002, WO-00074679, WO-09955679, WO-00105401, WO-00058361, WO-00114879, WO-00113112, WO-09954358.
- 35 27) One or more of a serotonin receptor agonist, antagonist or modulator, more particularly agonists, antagonists or modulators for 5HT<sub>1A</sub> (including VML 670),

5HT2A, 5HT2C, 5HT3 and/or 5HT6 receptors, including those described in WO-09902159, WO-00002550 and/or WO-00028993.

- 28) one or more of an androgen such as androsterone, dehydro-androsterone, testosterone, androstenedione and a synthetic androgen.
- 5 29) one or more of an oestrogen, such as oestradiol, oestrone, oestriol and a synthetic estrogen, such as oestrogen benzoate.
- 30) One or more of a modulator of transporters for noradrenaline, dopamine and/or serotonin, such as bupropion, GW-320659.
- 31) One or more of a purinergic receptor agonist and/or modulator.
- 10 32) One or more of a neurokinin (NK) receptor antagonist, including those described in WO-09964008.
- 33) One or more of an opioid receptor agonist, antagonist or modulator, preferably agonists for the ORL-1 receptor.
- 34) One or more of an agonist or modulator for oxytocin/vasopressin receptors, preferably a selective oxytocin agonist or modulator.
- 15 35) One or more of a PDE inhibitor, more particularly a PDE 2, 3, 4, 5, 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and most preferably a PDE5 inhibitor (see hereinafter), said inhibitors preferably having an IC<sub>50</sub> against the respective enzyme of less than 100nM. Suitable cGMP PDE5 inhibitors for the use
- 20 according to the present invention include:

the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP-A-0463756; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP-A-0526004; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international patent application WO 93/06104; the isomeric pyrazolo [3,4-d]pyrimidin-4-ones disclosed in published international patent application WO 93/07149; the quinazolin-4-ones disclosed in published international patent application WO 93/12095; the pyrido [3,2-d]pyrimidin-4-ones disclosed in published international patent application WO 94/05661; the purin-6-ones disclosed in published international patent application WO 94/00453; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international patent application WO 98/49166; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international patent application WO 99/54333; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP-A-0995751; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international patent application WO 00/24745; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP-A-0995750; the compounds disclosed in published international application WO95/19978; the compounds

25

30

35

disclosed in published international application WO 99/24433 and the compounds disclosed in published international application WO 93/07124. The pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international application WO 01/27112; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international application WO 01/27113; the compounds disclosed in EP-A-1092718 and the compounds disclosed in EP-A-1092719.

Further suitable PDE5 inhibitors for the use according to the present invention include: 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756); 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see EP-A-0526004); 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO98/49166); 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO99/54333 ); (+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, also known as 3-ethyl-5-{5-[4-ethylpiperazin-1-ylsulphonyl]-2-[(1R)-2-methoxy-1-methylethyl]oxy}pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO99/54333); 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, also known as 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridylsulphonyl}-4-ethylpiperazine (see WO 01/27113, Example 8); 5-[2-*iso*-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(1-methylpiperidin-4-yl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27113, Example 15); 5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-phenyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27113, Example 66); 5-(5-Acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27112, Example 124); 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27112, Example 132); (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-

dione (IC-351), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples 1, 3, 7 and 8; 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardeafil) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433; and the compound of example 11 of published international application WO93/07124 (EISAI); and compounds 3 and 14 from Rotella D P, *J. Med. Chem.*, 2000, 43, 1257.

Still other suitable PDE5 inhibitors include: 4-bromo-5-(pyridylmethylamino)-6-[3-(4-chlorophenyl)-propoxy]-3(2H)pyridazinone; 1-[4-[(1,3-benzodioxol-5-ylmethyl)amiono]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic acid, monosodium salt; (+)-cis-5,6a,7,9,9,9a-hexahydro-2-[4-(trifluoromethyl)-phenylmethyl-5-methyl-cyclopent-4,5]imidazo[2,1-b]purin-4(3H)one; furazlocillin; cis-2-hexyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]-imidazo[2,1-b]purin-4-one; 3-acetyl-1-(2-chlorobenzyl)-2-propylindole-6-carboxylate; 3-acetyl-1-(2-chlorobenzyl)-2-propylindole-6-carboxylate; 4-bromo-5-(3-pyridylmethylamino)-6-(3-(4-chlorophenyl) propoxy)-3-(2H)pyridazinone; 1-methyl-5(5-morpholinoacetyl-2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one; 1-[4-[(1,3-benzodioxol-5-ylmethyl)arnino]-6-chloro-2-quinazolinyl]-4-piperidinecarboxylic acid, monosodium salt; Pharmaprojects No. 4516 (Glaxo Wellcome); Pharmaprojects No. 5051 (Bayer); Pharmaprojects No. 5064 (Kyowa Hakko; see WO 96/26940); Pharmaprojects No. 5069 (Schering Plough); GF-196960 (Glaxo Wellcome); E-8010 and E-4010 (Eisai); Bay-38-3045 & 38-9456 (Bayer) and Sch-51866.

For treating FSD, the compounds of the invention may preferably be combined with one or more active ingredients selected from the list:

- a) a PDE5 inhibitor, more preferably 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil); (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351); 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardeafil); 5-[2-ethoxy-5-(4-

ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and pharmaceutically acceptable salts thereof;

- 5     b) an NPY Y1 inhibitor;
- c) a dopamine agonist such as apomorphine or a selective D<sub>2</sub>, D<sub>3</sub> or D<sub>2</sub>/D<sub>3</sub> agonist such as, pramipexole and ropirinol;
- d) a melanocortin receptor agonist or modulator or melanocortin enhancer, preferably melanotan II, PT-14, PT-141;
- 10    e) an agonist, antagonist or modulator for 5HT<sub>2C</sub>;
- f) an estrogen receptor modulator, estrogen agonists and/or estrogen antagonists, preferably raloxifene, tibolone or lasofoxifene;
- g) an androgen such as androsterone, dehydro-androsterone, testosterone, androstenedione and a synthetic androgen; and
- 15    h) an oestrogen, such as oestradiol, oestrone, oestriol and a synthetic estrogen, such as oestrogen benzoate.

For treating MED, the compounds of the invention may preferably be combined with one or more active ingredients selected from the list:

- 20    a) a PDE5 inhibitor, more preferably 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil); (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351); 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-
- 25    propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil); 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and pharmaceutically acceptable salts thereof;
- 30    b) an NPY Y1 inhibitor;
- c) a dopamine agonist (preferably apomorphine) or a selective D<sub>2</sub>, D<sub>3</sub> or D<sub>2</sub>/D<sub>3</sub> agonist such as, pramipexole and ropirinol;
- d) a melanocortin receptor agonist or modulator or melanocortin enhancer, preferably melanotan II, PT-14, PT-141; and
- 35    e) an agonist, antagonist or modulator for 5HT<sub>2C</sub>;

Particularly preferred combinations for treating FSD are the compounds of the present invention and one or more active ingredients selected from the list:

- 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil);
- 5 (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl) - pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351);
- 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil);
- 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-10 dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
- 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
- apomorphine;
- melanotan II;
- 15 PT-141;
- lasofoxifene;
- raloxifene;
- tibolone;
- an androgen such as androsterone, dehydro-androsterone, testosterone,
- 20 androstenedione and a synthetic androgen; and
- an oestrogen, such as oestradiol, oestrone, oestriol and a synthetic estrogen, such as oestrogen benzoate.

Particularly preferred combinations for treating MED are the compounds of the present invention and one or more active ingredients selected from the list:

- 25 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil);
- (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl) - pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351);
- 30 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil);
- 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
- 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
- 35 apomorphine;

melanotan II; and  
PT-141.

For treating cardiovascular disorders, particular hypertension, the compounds of the  
5 invention may be combined with one or more active ingredient selected from the list:

- a) angiotensin receptor blockers (ARB), such as losartan, valsartan, telmisartan, candesartan, irbesartan, eprosartan and olmesartan;
- b) calcium channel blockers (CCB) such as amlodipine;
- c) statins, such as atorvastatin;
- 10 d) PDE5 inhibitors, such as sildenafil, tadalafil, vardenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and; the  
15 pyrazolo[4,3-d]pyrimidin-4-ones disclosed in WO00/27848 particularly N-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-1-methyl-2-pyrrolidinepropanamide [DA-8159 (Example 68 of WO00/27848)];
- e) beta blockers, such as atenolol or carvedilol;
- f) ACE inhibitors, such as quinapril, enalapril and lisinopril;
- 20 g) alpha-blockers such as doxazosin;
- h) selective aldosterone receptor antagonists (SARA), such as eplerenone or spironolactone; and
- i) imidazoline I<sub>1</sub> agonists, such as rilmenidine and moxonidine.

25 If a combination of active agents are administered, then they may be administered simultaneously, separately or sequentially.

The compounds of the invention can be administered alone but, in human therapy will generally be administered in admixture with a suitable pharmaceutical excipient diluent  
30 or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

The present invention provides for a composition comprising a compound of formula (I) and pharmaceutically acceptable diluent or carrier.

For example, the compounds of the invention, can be administered orally, buccally or sublingually in the form of tablets, capsules (including soft gel capsules), ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, dual-, controlled-release or pulsatile delivery applications. The compounds of the invention may also be administered via fast dispersing or fast dissolving dosage forms.

Modified release and pulsatile release dosage forms may contain excipients such as those detailed for immediate release dosage forms together with additional excipients that act as release rate modifiers, these being coated on and/or included in the body of the device. Release rate modifiers include, but are not exclusively limited to, hydroxypropylmethyl cellulose, methyl cellulose, sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, polyethylene oxide, Xanthan gum, Carbomer, ammonio methacrylate copolymer, hydrogenated castor oil, carnauba wax, paraffin wax, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, methacrylic acid copolymer and mixtures thereof. Modified release and pulsatile release dosage forms may contain one or a combination of release rate modifying excipients. Release rate modifying excipients may be present both within the dosage form i.e. within the matrix, and/or on the dosage form, i.e. upon the surface or coating.

20

Fast dispersing or dissolving dosage formulations (FDDFs) may contain the following ingredients: aspartame, acesulfame potassium, citric acid, croscarmellose sodium, crospovidone, diascorbic acid, ethyl acrylate, ethyl cellulose, gelatin, hydroxypropylmethyl cellulose, magnesium stearate, mannitol, methyl methacrylate, mint flavouring, polyethylene glycol, fumed silica, silicon dioxide, sodium starch glycolate, sodium stearyl fumarate, sorbitol, xylitol. The terms dispersing or dissolving as used herein to describe FDDFs are dependent upon the solubility of the drug substance used, i.e. where the drug substance is insoluble a fast dispersing dosage form can be prepared and where the drug substance is soluble a fast dissolving dosage form can be prepared.

30

The compositions of the invention may be administered by direct injection. The composition may be formulated for parenteral, mucosal, intramuscular, intravenous, subcutaneous, ocular, intraocular or transdermal administration. Depending upon the need, the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.

35

The term "administered" includes delivery by viral or non-viral techniques. Viral delivery mechanisms include but are not limited to adenoviral vectors, adeno-associated viral (AAV) vectos, herpes viral vectors, retroviral vectors, lentiviral vectors, and baculoviral vectors.

5 Non-viral delivery mechanisms include lipid mediated transfection, liposomes, immunoliposomes, lipofectin, cationic facial amphiphiles (CFAs) and combinations thereof.

The routes for such delivery mechanisms include but are not limited to mucosal, nasal, oral, parenteral, gastrointestinal, topical, or sublingual routes.

10 In addition or in the alternative the compositions (or component parts thereof) of the present invention may be administered by direct injection. In addition or in the alternative the compositions (or component parts thereof) of the present invention may be administered topically (preferably to the genitalia). In addition or in the alternative the compositions (or component parts thereof) of the present invention may be administered  
15 by inhalation. In addition or in the alternative the compositions (or component parts thereof) of the present invention may also be administered by one or more of: a mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution such as by an oral route, or by a parenteral route where delivery is by an injectable form, such as, for example, by a rectal, ophthalmic (including intravitreal or intracameral),  
20 nasal, topical (including buccal and sublingual), intrauterine, vaginal or parenteral (including subcutaneous, intraperitoneal, intramuscular, intravenous, intradermal, intracranial, intratracheal, and epidural) transdermal, intraperitoneal, intracranial, intracerebroventricular, intracerebral, intravaginal, intrauterine, or parenteral (e.g., intravenous, intraspinal, subcutaneous, transdermal or intramuscular) route.

25 By way of example, the pharmaceutical compositions of the invention may be administered in accordance with a regimen of 1 to 10 times per day, such as once or twice per day. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the  
30 specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.

35 Hence, the term "administered" includes but is not limited to delivery by a mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution; a

parenteral route where delivery is by an injectable form, such as, for example, an intravenous, intramuscular or subcutaneous route.

Such tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethyl cellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof:

The compounds of the invention can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion techniques. In addition, they may be administered in the form of an implant. For such parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art. Parenteral formulations may be formulated for immediate-, delayed-, modified-, sustained-, dual-, controlled-release or pulsatile delivery.

The following dosage levels and other dosage levels herein are for the average human subject having a weight range of about 65 to 70 kg. The skilled person will readily be able to determine the dosage levels required for a subject whose weight falls outside this range, such as children and the elderly.



For oral and parenteral administration to human patients, the daily dosage level of the compounds of the invention or salts or solvates thereof will usually be from 10 to 1000 mg (in single or divided doses).

5 Thus, for example, tablets or capsules of the compounds of the invention or salts or solvates thereof may contain from 5 to 1000 mg, such as 5 to 500 mg of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular  
10 patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention. The skilled person will also appreciate that, in the treatment of certain conditions (including FSD and MED), compounds of the invention may be taken as a single dose on an "as required" basis (i.e. as needed or desired).

15 The compounds of the invention can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane,  
20 dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A [trade mark] or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA [trade mark]), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of  
25 the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

30 Aerosol or dry powder formulations are preferably arranged so that each metered dose or "puff" contains from 1 to 50 mg of a compound of the invention for delivery to the patient. The overall daily dose with an aerosol will be in the range of from 1 to 50 mg which may be administered in a single dose or, more usually, in divided doses  
35 throughout the day.

Alternatively, compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topically (preferably to the genitalia) in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The compounds of the invention may also be dermally administered. The compounds of the invention may also be transdermally administered, for example, by the use of a skin patch. They may also be administered by the ocular, pulmonary or rectal routes.

For ophthalmic use, compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

For application topically to the skin (preferably to the genitalia), compounds of the invention can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

The compounds of the invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

In a preferred embodiment, the compounds of the invention are delivered systemically (such as orally, buccally and sublingually), more preferably orally. Preferably such systemic (most preferably oral) administration is used to treat female sexual dysfunction, preferably FSAD.

Thus in a particularly preferred embodiment, there is provided the use of the compounds of the invention in the manufacture of a systemically delivered (preferably orally delivered) medicament for the treatment or prophylaxis of FSD, more preferably FSAD.

5

A preferred oral formulation uses immediate release tablets; or fast dispersing or dissolving dosage formulations (FDDFs).

10 In a further preferred embodiment, the compounds of the invention are administered topically, preferably directly to the female genitalia, especially the vagina.

Since NEP is present throughout the body, it is very unexpected that the compounds of the invention can be administered systemically and achieve a therapeutic response in the female genitalia without provoking intolerable (adverse) side effects. In  
15 EP 1 097 719-A1 and the animal model hereinafter, we have shown that NEP inhibitors administered to a rabbit model (*in vivo*) systemically increased genital blood flow, upon sexual arousal (mimiced by pelvic nerve stimulation) without adversely affecting cardiovascular parameters, such as causing a significant hypotensive or hypertensive.

20 Preferably the compounds of the invention are administered for the treatment of FSD in the sexually stimulated patient (by sexual stimulation we mean to include visual, auditory or tactile stimulation). The stimulation can be before, after or during said administration.

25 Thus the compounds of the invention enhance the pathways/mechanisms that underlie sexual arousal in the female genitalia restoring or improving the sexual arousal response to sexual stimulation.

Thus a preferred embodiment provides the use of a compound of the invention in the preparation of a medicament for the treatment or prophylaxis of FSD in the stimulated  
30 patient.

For veterinary use, a compound of the invention, is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most  
35 appropriate for a particular animal.

The following formulation examples are illustrative only and are not intended to limit the scope of the invention . "Active ingredient" means a compound of the invention.

Formulation 1: A tablet is prepared using the following ingredients:

	weight/mg
Active ingredient	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	5
Total	665

5 the components are blended and compressed to form tablets.

Formulation 2: An intravenous formulation may be prepared as follows:

Active ingredient	100mg
Isotonic saline	1,000ml

10 Typical formulations useful for administering the compounds of the invention topically to the genitalia are as follows:

Formualtion 3: A spray

Active ingredient (1.0%) in isopropanol (30%) and water.

15 Formulation 4: A foam

Active ingredient, acetic acid glacial, benzoic acid, cetyl alcohol, methyl parahydroxybenzoate, phosphoric acid, polyvinyl alcohol, propylene glycol, sodium carboxymethylcellulose, stearic acid, diethyl stearamide, van Dyke perfume No. 6301, purified water and isobutane.

20

Formulation 5: A gel

Active ingredient, docusate sodium BP, isopropyl alcohol BP, propylene glycol, sodium hydroxide, carbomer 934P, benzoic acid and purified water.

25 Formulation 6: A Cream

Active ingredient, benzoic acid, cetyl alcohol, lavender, compound 13091, methylparaben, propylparaben, propylene glycol, sodium carboxymethylcellulose,

sodium lauryl sulfate, stearic acid, triethanolmine, acetic acid glacial, castor oil, potassium hydroxide, sorbic acid and purified water.

Formulation 7: A pessary

- 5 Active ingredient, cetomacrogol 1000 BP, citric acid, PEG 1500 and 1000 and purified water.

The invention additionally includes:

- 10 (i) A pharmaceutical composition including a compound of the invention, together with a pharmaceutically acceptable excipient, diluent or carrier.
- (ii) A compound of the invention for use as a medicament.
- (iii) The use of a compound of the invention as a medicament for treating or preventing a condition for which a beneficial therapeutic response can be obtained by the inhibition of neutral endopeptidase.
- 15 (iv) The use of a compound of the invention as a medicament for treating or preventing hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder or sexual pain disorder, preferably sexual arousal disorder, orgasmic disorder or sexual pain disorder, more preferably sexual arousal disorder.
- 20 (v) A method of treating FSD or MED in a mammal including treating said mammal with an effective amount of a compound of the invention.
- (vi) An FSD or MED treating pharmaceutical composition comprising a compound of the invention together with a pharmaceutically acceptable excipient, diluent or carrier.
- (vii) A compound of the invention for use in treating FSD or MED.
- 25 (viii) The use of a compound of the invention in the manufacture of a medicament for treating or preventing FSD or MED.

The invention is illustrated by the following non-limiting examples in which the following abbreviations and definitions are used:

30

Arbacel®	filter agent
br	broad
Boc	<i>tert</i> -butoxycarbonyl
CDI	carbonyldiimidazole
$\delta$	chemical shift
d	doublet

$\Delta$	heat
DCCI	dicyclohexylcarbodiimide
DCM	dichloromethane
DMA	dimethylacetamide
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethylsulfoxide
ES <sup>+</sup>	electrospray ionisation positive scan
ES <sup>-</sup>	electrospray ionisation negative scan
Ex	Example
h	hours
HOBt	1-hydroxybenzotriazole
HPLC	high pressure liquid chromatography
m/z	mass spectrum peak
min	minutes
MS	mass spectrum
NMR	nuclear magnetic resonance
Prec	precursor
Prep	preparation
q	quartet
s	singlet
t	triplet
Tf	trifluoromethanesulfonyl
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin layer chromatography
TS <sup>+</sup>	thermospray ionisation positive scan
WSCDI	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

<sup>1</sup>H Nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts ( $\delta$ ) are given in parts-per-million downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. The following abbreviations have been used for common solvents: CDCl<sub>3</sub>, deuteriochloroform; DMSO, dimethylsulphoxide. The abbreviation psi means pounds per square inch and LRMS means low resolution mass spectrometry. Where thin layer chromatography (TLC) has been used it refers to silica gel TLC using silica gel 60 F<sub>254</sub> plates, R<sub>f</sub> is the

distance travelled by a compound divided by the distance travelled by the solvent front on a TLC plate. Melting points were determined using a Perkin Elmer DSC7 at a heating rate of 20°C/minute).


- 5 The powder X-ray diffraction (PXRD) pattern was determined using a SIEMENS D5000 powder X-ray diffractometer fitted with an automatic sample changer, a theta-theta goniometer, automatic beam divergence slits, a secondary monochromator and a scintillation counter. The sample was prepared for analysis by packing the powder on to a silicon wafer specimen mount. The specimen was rotated whilst being irradiated with  
10 copper K-alpha<sub>1</sub> X-rays (wavelength = 1.5406 Ångstroms) with the X-ray tube operated at 40kV/40mA. The analysis was performed with the goniometer running in step-scan mode set for a 5 second count per 0.02° step over a two theta range of 3° to 40°. In the results tables "Angle 2-Theta" is related to the interplanar spacing of the crystal, and the intensity is given as a percentage of the greatest peak ( $I/I_1$ ).

15

- The skilled crystallographer will appreciate that the relative intensities of the peaks may vary due to a number of factors such as orientation effects of crystals in the X-ray beam or the purity of the material being analysed or the degree of crystallinity of the sample. The peak positions may vary in sample height but the peak positions will remain  
20 substantially as tabulated. In addition, measurements using a different wavelength may result variation in the shift according to the Bragg equation -  $n\lambda = 2d \sin \theta$ . These variations generated by use of alternative wavelengths are within the scope of the present invention.

25 **Example 1**

**(*R*)-2-Methyl-3-(1-{[3-(2-methyl-1,3-benzothiazol-6-yl)propyl]carbamoyl}cyclopentyl)propanoic acid**



- 30 *tert*-Butyl ester (7.4g, 16.7 mmol) was dissolved in dichloromethane (10 mL) and trifluoroacetic acid (10 mL) was added and the mixture stirred at room temperature for 5 hours. The reaction was quenched by the addition of potassium carbonate (10% aqueous solution) to adjust the pH to *ca.* 3 (*ca.* 120 mL required). The resulting mixture was extracted with dichloromethane (3 x 100 mL) and the  
35 combined organic layers dried with MgSO<sub>4</sub> and evaporated. The residue was purified by flash chromatography [SiO<sub>2</sub>; methanol in dichloromethane 1% to 2%] to afford the desired acid as a clear oil (5.66 g, 87%). This batch was combined with 1.4 g of material from a previous run and stirred in pentane (100 mL) for 3 hours. The

5

10

15

15

15

## Analytical

**Ambient**  
**225, 254 nm**  
**A: Water:MeCN:TFA**  
**95:5: 0.1 % (v/v)**

B: MeCN  
 Linear gradient elution  
 see below  
 Flow rate 1 ml/min

Solvent gradient conditions:


Time	%B
0.0	0
0.2	0
5.0	95
7.1	95
8.0	0

- 5 Chiral purity was assessed as 98% by capillary electrophoresis by comparison to an authentic sample of the opposite enantiomer prepared by a similar route, using the conditions described below:

CE conditions	
Capillary	Agilent fused silica extended light path capillary 64.5 cm (56 cm effective length), 50 $\mu$ m I.D.
Temperature	15 °C
Detection	UV at 230, 254 and 260 nm
Sample dissolution	c.a.1 mg/ml in run buffer:water:methanol:acetone; (1:10:1:0.5)
System/ data file	HP 3DCE (see attached printouts)
Injection	4 seconds 50 mbar sample then 2 seconds 50 mbar water
Run buffer	250 mg $\gamma$ -cyclodextrin and 50 mg SBE- $\gamma$ -cyclodextrin dissolved in pH 9.3 borax buffer, 50 mM (Agilent CE solution), 5 ml.
Pre-conditioning	New capillary: 10 minutes 930 mBar 1.0 M NaOH Between runs: 2 minutes 930 mbar 0.1 M NaOH, rinse 2 sec water, 4 minutes 930 mBar run buffer
Voltage	25 kV (ramped 0-25kV over 30 seconds)
Run Time	20 minutes

## Example 2


- 10 3-(1-{[3-(2-ethyl-1,3-benzothiazol-6-yl)propyl]carbamoyl}cyclopentyl)propanoic acid




This compound was prepared using the procedure described in Example 1, starting from the ester product from preparation 6.

15

$^1\text{H}$  NMR ( $d_6$ -DMSO, 400 MHz)  $\delta_{\text{H}}$ : 7.89 (1H, d), 7.63 (1H, s), 7.25 (1H, d), 5.69 (1H, brs), 3.37 (2H, m), 3.15 (2H, q), 2.76 (2H, m), 2.31 (2H, m), 1.96-1.87 (6H, m), 1.70-1.55 (4H, m), 1.47 (3H, t);  $m/z$  ( $\text{ES}^+$ ) 411 ( $\text{MNa}^+$ ), 389 ( $\text{MH}^+$ );  $m/z$  ( $\text{ES}^-$ ) 387 ( $\text{MH}^+$ )

Preparation 1di(*tert*-butyl) 3-(2-methyl-1,3-benzothiazol-6-yl)propylimidodicarbonate

- 5 Di(*tert*-butyl) allylimidodicarbonate [*Bioorganic & Medicinal Chemistry Letters*, 1999, 7, (1625-1636)] (8.75g, 34 mmol) was treated with 9-BBN [Aldrich] (136mL, 0.5M solution in tetrahydrofuran, 2 equivalents, 68 mmol) at 0 °C, and the solution stirred at room temperature for 45 min. Potassium phosphate (16 mL, 3M aqueous solution, 2.5 equivalents, 48 mmol) was added cautiously and the reaction flask then covered with aluminium foil. A solution of 6-bromo-2-methylbenzothiazole [*J. Chem. Soc.* 10 1936, 1225; DE3528032A1] (7.80g, 34 mmol, 1 equivalent) in dimethylformamide (50 mL) was added followed by 1,1'-bis(diphenylphosphino)ferrocene palladium(II) dichloride -dichloromethane 1:1 complex (2.77 g, 3.4 mmol, 0.1 equivalents) and the reaction mixture stirred at room temperature for 18 hours. The reaction mixture 15 was concentrated *in vacuo* and the residue purified by column chromatography [SiO<sub>2</sub>, pentane: ethyl acetate, 5:1 then 3:1] to afford the desired product as a clear oil (11.2 g, 84%). <sup>1</sup>H nmr analysis showed the material showed slight contamination with traces of solvent and 9-BBN residues. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ<sub>H</sub>: 7.81 (1H, d), 7.60 (1H, s), 7.23 (1H, d), 3.60 (2H, t), 2.77 (3H, s), 2.71 (2H, t), 1.97-1.88 20 (2H, m), 1.45 (18H, s): *m/z* (APCI<sup>+</sup>) 407 (MH<sup>+</sup>), 307 (MH<sup>+</sup>-Boc)


Preparation 2Di(*tert*-butyl) 3-(2-ethyl-1,3-benzothiazol-6-yl)propylimidodicarbonate

- 25 This 2-ethylthiazole intermediate was prepared in an analogous fashion that of preparation 1 using 6-bromo-2-ethylbenzothiazole [*Bull. Soc. Chim. Fr.* 1967, 2812-23] as the aryl bromide component. <sup>1</sup>H NMR (d<sub>6</sub>-DMSO, 400 MHz) δ<sub>H</sub>: 7.84 (1H, d), 7.64 (1H, s), 7.26 (1H, d), 3.60 (2H, m), 3.12 (2H, q), 2.73 (2H, t), 1.07-1.86 (2H, m), 1.47 (9H, s), 1.45 (3H, t): *m/z* (APCI<sup>+</sup>) 421 (MH<sup>+</sup>), 321 (MH<sup>+</sup>-Boc)

30

Preparation 3

3-(2-methyl-1,3-benzothiazol-6-yl)propylamine dihydrochloride salt


**.2HCl**

- 35 *N,N*-di-*tert*-butoxycarbonyl-3-(2-methyl-1,3-benzothiazol-6-yl)propylamine (11.2g, 27.5 mmol) was dissolved in 1,4-dioxan (30 mL) and treated with hydrogen chloride (25 mL, 4M solution in 1,4-dioxan, 100 mmol) and the solution stirred at room

temperaure for 18 hours. The reaction mixture was evaporated to a white solid which was triturated with a mixture of pentane and diethyl ether (3:1) to afford the desired amine bis HCl salt as a white solid (6.05g, 78%). <sup>1</sup>H NMR (d<sub>6</sub>-DMSO, 400 MHz) δ<sub>H</sub>: 7.98 (3H, brs), 7.85 (1H, s), 7.81 (1H, d), 7.31 (1H, d), 2.78-2.73 (4H, m), 2.75 (3H, s), 1.94-1.85 (2H, m): *m/z* (APCI<sup>+</sup>) 207.

#### Preparation 4

3-(2-ethyl-1,3-benzothiazol-6-yl)propylamine dihydrochloride salt




This 2-ethylthiazole intermediate was prepared in an analogous fashion that of preparation 3, except that dichloromethane was used as the initial solvent in place of dioxan.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ<sub>H</sub>: 8.04 (1H, s), 7.95 (1H, d), 7.62 (1H, d), 3.36 (2H, q), 3.02-2.88 (4H, m), 2.10-2.02 (2H, m), 1.53 (3H, t): *m/z* 221 (MH<sup>+</sup>)

#### Preparation 5

*tert*-Butyl (2*R*)-2-methyl-3-[1-({[3-(2-methyl-1,3-benzothiazol-6-yl)propyl]amino}carbonyl)cyclopentyl]propanoate




A solution of 1-[(2*R*)-3-*tert*-butoxy-2-methyl-3-oxopropyl]cyclopentanecarboxylic acid [WO0279143A1] (6.8 g, 26.5 mmol) in isopropyl acetate (30 mL) was added to a solution of carbonyl diimidazole (4.76 g, 29.3 mmol, 1.1 equivalents) in isopropyl acetate (60 mL) and the mixture heated for 3 hours at 60 °C and then overnight at room temperature. An aliquot was removed and evaporated to dryness and tested by <sup>1</sup>H nmr spectroscopy. This indicated the reaction has proceeded to approximately 90% conversion (Me doublet for starting acid δ 1.15, Me doublet for acyl imidazolid δ 1.05). A further portion of carbonyl diimidazole (645 mg, 4 mmol, 0.15 equivalents) was added and the mixture stirred at 60 °C for a further 1 hour. The reaction mixture was cooled to 40 °C and triethylamine (4.3 mL, 31 mmol, 1.1 equivalents) and 3-(2-methyl-1,3-benzothiazol-6-yl)propylamine dihydrochloride salt from preparation 3 (7.1 g, 25.4 mmol, 0.96 equivalents) were added and the mixture heated at 60 °C overnight. Thin layer chromatography showed the reaction was not complete, therefore a further portion of amine dihydrochloride was added (650mg, 2.3 mmol, 0.09 equivalents) together with triethylamine (330μL, 2.3 mmol, 0.09 equivalents) and the mixture heated at 60 °C overnight. The reaction mixture was allowed to cool to room temperature and then diluted with water (120 mL) and 2M hydrochloric acid (120 mL). The mixture was extracted with diethyl ether (2 x 400 mL) and the combined extracts washed with 2M NaOH (2 x 100 mL), dried (MgSO<sub>4</sub>) and evaporated. The oily residue obtained was purified by flash chromatography [SiO<sub>2</sub>, methanol in dichloromethane 0.5% to 1.5%] to afford the title compound as a clear oil (11.5 g, 98%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ<sub>H</sub>: 7.84 (1H, d), 7.64 (1H, s), 7.23 (1H, d), 5.76 (1H, brs), 3.34-3.23 (2H, m), 2.77 (2H, t), 2.35-

2.27 (1H, m), 2.06-1.99 (2H, m), 1.91-1.85 (3H, m), 1.68-1.50 (7H, m), 1.42 (9H, s), 1.09 (3H, d).  $m/z$  (ES<sup>+</sup>) 467 MNa<sup>+</sup>.

#### Preparation 6

5 *tert*-butyl 3-[1-({[3-(2-ethyl-1,3-benzothiazol-6-yl)propyl]amino}carbonyl)cyclopentyl]propanoate



10 *tert*-Butyl-3-1-carboxycyclopentyl)propanoate [W00279143A1] (180 mg, 0.7 mmol) was mixed together with the amine dihydrochloride from preparation 4 (180mg, 0.65 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (135 mg, 0.7 mmol), 1-hydroxybenzotriazole (95 mg, 0.7 mmol) and triethylamine (400  $\mu$ L, 2.8 mmol) in dimethyl formamide (7 mL). The reaction mixture was stirred at 60 °C overnight. After cooling to room temperature the mixture was evaporated *in vacuo*

15 and the residue diluted with water (50mL). The mixture was extracted with diethyl ether (3 x 50 mL) and the combined organic fractions dried with MgSO<sub>4</sub> and then evaporated. Purification by flash chromatography [SiO<sub>2</sub>;ethyl acetate in pentane (15% to 20%)] to afford the desired compound as a light brown oil. . <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta_H$ : 7.87 (1H, d), 7.65 ( 1H, s), 7.26 (1H, d), 5.63 (1H, brs), 3.30 (2H, q), 3.12 (2H, q), 2.75 (2H, t), 2.20-2.14 (2H, m), 1.98-1.80 (6H, m), 1.68-

20 1.58 (5H, m), 1.45 (3H, t), 1.42 (9H, s):  $m/z$  (ES<sup>+</sup>) 467 (MNa<sup>+</sup>), 445 (MH<sup>+</sup>)